Pharma Inc agrees to cap margins on non-price control drugs at 30%
Big pharma companies with generic divisions — such as Sun Pharma, Cipla and Lupin — will have to reduce MRP. Source: Pharma Inc agrees to cap margins on non-price control drugs at 30%
Pharma wrap: NPPA drug price hike and the need for robust price regulation of medicines
NPPA said it considered the view that unviability of these formulations should not lead to a situation where these drugs become unavailable in the market and that the public is forced to switch to costly alternatives
Pharma Inc agrees to cap margins on non-price control drugs at 30%
Big pharma companies with generic divisions — such as Sun Pharma, Cipla and Lupin — will have to reduce MRP. Source: Pharma Inc agrees to cap margins on non-price control drugs at 30%
Monsanto ruling may hit innovation
The Monsanto judgment highlights the need to bring scientific and technical expertise into the judicial process
Why the new arbitration bill is much ado about nothing
The bill’s particularly failure is to provide for a fixed the period of time for completion of arbitration proceedings.Get latest Legal online at cnbctv18.com Source: Why the new arbitration bill is much ado about nothing
Global Focus: Clinical Trials in India – Food and Drug Law Institute (FDLI)
With India’s goal to transform itself into a global innovation hub by 2020, the R&D sector is poised to witness robust growth in the coming years. Government policy includes targeted fiscal incentives and streamlined procedures
MJ Akbar vs #MeToo Movement: How defamation cases play out in India
To constitute the offence of defamation, there has to be imputation and the imputation has to be made in the manner as prescribed in the provision.
Like in any criminal case, the offence of defamation has to be proved beyond any reasonable doubt and the trial includes examination of ocular and documentary evidence of both sides, arguments etc.
Why biosimilars are a huge opportunity for the Indian biopharmaceutical industry
The global biosimilars market is estimated to touch $15 billion by 2020. There is increased activity and growth in the biosimilars market globally with some of the best-selling biologics going off-patent.
To meet its global aspirations as a vital supplier of biosimilars, India must address some of the fundamental concerns that investors have about the Indian legal and regulatory framework for biopharmaceuticals.
E-cigarettes: Regulation and not prohibition is the answer
The concerns surrounding e-cigarettes have been addressed through reasonable checks and balances rather than extreme restrictions in these jurisdictions.Get latest Economy online at cnbctv18.com Source: E-cigarettes: Regulation and not prohibition is the answer
Sequential opposition delaying drug patents
Price is not the only barrier faced by patients in India. Access to all medicines is a formidable
issue – even to over the counter generic generic medicines. Medicines which are free and part of
Government programmes too do not reach those who need them the most. Further, poor patients
do not have access to even the most basic healthcare. In order to improve public health requires a
collective long-term commitment is required from the government, healthcare providers, and
others comprising the healthcare system, as well as establishment of infrastructure at the local leve
